<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589626</url>
  </required_header>
  <id_info>
    <org_study_id>1245.106</org_study_id>
    <nct_id>NCT02589626</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA</brief_title>
  <official_title>A 52-week Randomised, Double-blind, Parallel Group, Safety and Efficacy Study of Empagliflozin Once Daily as add-on Therapy to Glucagon-like Peptide-1 Receptor Agonist in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study
      of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus
      with insufficient glycaemic control
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2015</start_date>
  <completion_date type="Actual">June 2, 2017</completion_date>
  <primary_completion_date type="Actual">June 2, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percentage of patients with drug-related Adverse events (AEs) during 52 weeks of treatment are presented</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c After 52 Weeks of Treatment</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>Change from baseline in HbA1c after 52 weeks of treatment is presented. Means presented are the adjusted means.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>empagliflozin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin 10mg</intervention_name>
    <arm_group_label>empagliflozin 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin 25 mg</intervention_name>
    <arm_group_label>empagliflozin 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For blinding purposes</description>
    <arm_group_label>empagliflozin 10 mg</arm_group_label>
    <arm_group_label>empagliflozin 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of type 2 diabetes mellitus

          -  Male and female patients on diet and exercise regimen who are pre-treated with
             Liraglutide at 0.9 mg/day alone for at least 10 weeks prior to screening must be
             &gt;=7.0% and &lt;=10.0% at screening

          -  Male and female patients on diet and exercise regimen who are pre-treated with
             Liraglutide at 0.9 mg/day and one of oral antidiabetic drug (OAD) for at least 10
             weeks prior to Visit 1 must be &gt;=7.0% and &lt;=9.0% at screening and &gt;=7.0% and &lt;=10.0%
             at placebo run-in

          -  Male and female patients on diet and exercise regimen who are pre-treated with OAD
             alone for at least 10 weeks prior to Visit 1 must be &gt;=7.0% and &lt;=10.0% at both
             screening and placebo run-in

          -  Age at informed consent must be &gt;=20 years

          -  BMI at screening must be &lt;=40 kg/m2

          -  Further inclusion criteria apply

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose values &gt;270 mg/dL (&gt;15.0 mmol/L) after an
             overnight fast during switch/washout/placebo run-in period and confirmed by a second
             measurement

          -  Patients who are drug-naïve at screening visit or treat with any of insulin,
             thiazolidine dione, sodium-glucose co-transporter 2 (SGLT-2) inhibitor within 10 weeks
             prior to informed consent.

          -  Acute coronary syndrome, stroke or transient ischemic attack within 12 weeks prior to
             informed consent

          -  Indication of liver disease, defined by serum levels of either alanine
             aminotransferase, aspartate aminotransferase, or alkaline phosphatase above 3 x upper
             limit of normal as determined during screening and/or switch/washout/placebo run-in
             period

          -  Impaired renal function, defined as estimated glomerular filtration rate (eGFR) &lt;45
             mL/min/1.73m2 (Japanese equation) as determined during screening and/or
             switch/washout/placebo run-in period

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kunisaki Makoto Clinic</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <zip>819-0168</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seino I.M. Clinic, Fukushima, I.M.</name>
      <address>
        <city>Fukushima, Koriyama</city>
        <zip>963-8851</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Kokan Fukuyama Hospital</name>
      <address>
        <city>Hiroshima, Fukuyama</city>
        <zip>721-0927</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakakinen Clinic</name>
      <address>
        <city>Ibaraki, Naka</city>
        <zip>311-0113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kubota Clinic</name>
      <address>
        <city>Kanagawa, Kawasaki</city>
        <zip>214-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Yuga Higashirinkan Kaneshiro Diabetes Clinic</name>
      <address>
        <city>Kanagawa, Yamato-shi</city>
        <zip>242-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Minoru Clinic</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <zip>232-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokkaichi Diabetes Clinic</name>
      <address>
        <city>Mie, Yokkaichi</city>
        <zip>510-0829</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiraiwa Medical Clinic</name>
      <address>
        <city>Osaka, Kashiwara-shi</city>
        <zip>582-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC Nishi-umeda Clinic</name>
      <address>
        <city>Osaka, Osaka-shi</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OCROM Clinic</name>
      <address>
        <city>Osaka, Suita</city>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuwa Clinic</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo-Eki Center-building Clinic</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minamino Heart Clinic</name>
      <address>
        <city>Tokyo, Hachioji</city>
        <zip>192-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ToCROM Clinic</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <zip>160-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinjuku Research Park Clinic</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 27, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <results_first_submitted>May 31, 2018</results_first_submitted>
  <results_first_submitted_qc>January 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2019</results_first_posted>
  <last_update_submitted>January 4, 2019</last_update_submitted>
  <last_update_submitted_qc>January 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02589626/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02589626/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were entered in the trial and randomised in a 1:1 ratio to receive treatment.</recruitment_details>
      <pre_assignment_details>All subjects were screened for eligibility to participate in the trial. Subjects attended specialist site which would then ensure that they (the subjects) met all strictly implemented inclusion/exclusion criteria. Subjects were not randomised to trial treatment if any one of the specific entry criteria was violated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Empagliflozin 10 mg</title>
          <description>Patients were orally administered film-coated tablet of Empagliflozin 10 milligram (mg) once daily in the morning for 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>Empagliflozin 25 mg</title>
          <description>Patients were orally administered film-coated tablet of Empagliflozin 25 mg once daily in the morning for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32">Entered are treated patients</participants>
                <participants group_id="P2" count="33">Entered are treated patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other than the reason specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set:
The full analysis set (FAS) consisted of all patients in the treated set (TS) who were treated with at least 1 dose of the randomised study drug and had a baseline HbA1c assessment. The assignment of patients to treatment groups was based on the randomised study drug at time of randomisation.</population>
      <group_list>
        <group group_id="B1">
          <title>Empagliflozin 10 mg</title>
          <description>Patients were orally administered film-coated tablet of Empagliflozin 10 milligram (mg) once daily in the morning for 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>Empagliflozin 25 mg</title>
          <description>Patients were orally administered film-coated tablet of Empagliflozin 25 mg once daily in the morning for 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Full analysis set The full analysis set (FAS) consisted of all patients in the TS who were treated with at least 1 dose of the randomised study drug and had a baseline HbA1c assessment. The assignment of patients to treatment groups was based on the randomised study drug at time of randomisation.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.6" spread="9.8"/>
                    <measurement group_id="B2" value="58.9" spread="9.3"/>
                    <measurement group_id="B3" value="57.3" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline glycosylated haemoglobin A1c (HbA1c)</title>
          <population>FAS</population>
          <units>% of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.83" spread="0.80"/>
                    <measurement group_id="B2" value="8.68" spread="0.87"/>
                    <measurement group_id="B3" value="8.76" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment</title>
        <description>Percentage of patients with drug-related Adverse events (AEs) during 52 weeks of treatment are presented</description>
        <time_frame>52 weeks</time_frame>
        <population>The treated set (TS) consisted of all patients who were randomised and treated with at least 1 dose of the study drug. The assignment of patients to treatment group was based on the first study drug intake in the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 10 mg</title>
            <description>Patients were orally administered film-coated tablet of Empagliflozin 10 milligram (mg) once daily in the morning for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 25 mg</title>
            <description>Patients were orally administered film-coated tablet of Empagliflozin 25 mg once daily in the morning for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment</title>
          <description>Percentage of patients with drug-related Adverse events (AEs) during 52 weeks of treatment are presented</description>
          <population>The treated set (TS) consisted of all patients who were randomised and treated with at least 1 dose of the study drug. The assignment of patients to treatment group was based on the first study drug intake in the double-blind treatment period.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c After 52 Weeks of Treatment</title>
        <description>Change from baseline in HbA1c after 52 weeks of treatment is presented. Means presented are the adjusted means.</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>Full Analysis Set (Observed cases (OC))</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 10 mg</title>
            <description>Patients were orally administered film-coated tablet of Empagliflozin 10 milligram (mg) once daily in the morning for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 25 mg</title>
            <description>Patients were orally administered film-coated tablet of Empagliflozin 25 mg once daily in the morning for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c After 52 Weeks of Treatment</title>
          <description>Change from baseline in HbA1c after 52 weeks of treatment is presented. Means presented are the adjusted means.</description>
          <population>Full Analysis Set (Observed cases (OC))</population>
          <units>% of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.15"/>
                    <measurement group_id="O2" value="-0.77" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs which occurred through the treatment phase and throughout the residual effect period (REP); up to 53 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Empagliflozin 10 mg</title>
          <description>Patients were orally administered film-coated tablet of Empagliflozin 10 milligram (mg) once daily in the morning for 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin 25mg</title>
          <description>Patients were orally administered film-coated tablet of Empagliflozin 10 mg once in the morning for 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property right</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

